Stockreport

Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates

Climb Bio, Inc.  (CLYM) 
PDF PrisMN Phase 2 trial of budoprutug in Primary Membranous Nephropathy (pMN) initiated  Phase 1 trial of budoprutug subcutaneous formulation initiated, with initial data [Read more]